CLINICAL TRIALS PROFILE FOR TRIAZOLAM
✉ Email this page to a colleague
All Clinical Trials for triazolam
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00671632 ↗ | Behavioral and Subjective Efficacy of Ramelteon in Subjects With a History of Polydrug Abuse | Completed | Takeda | Phase 2 | 2003-06-01 | The purpose of this study is to determine the relative abuse potential of ramelteon, once daily (QD), compared to triazolam in subjects with a history of drug abuse. |
| NCT00695630 ↗ | Flumazenil Reversal of Oral Triazolam | Completed | National Institutes of Health (NIH) | Phase 1/Phase 2 | 2006-09-01 | An increase in the utilization of anesthesia and sedation medications by non-anesthesiologists, including dentists, has grown dramatically. This has been prompted, in part, by the need for pharmacological tools to address high levels of fear and anxiety about dental care among the US population and the evidence of oral health disparities among those who are fearful . Given the prevalence of dental fear in the general population and in the various populations with the greatest burden of oral diseases, effective sedation techniques are needed that are safe and effective in the hands of general dentists that make up the "front line" in the efforts to reduce oral health disparities. This study is to determine whether, when compared to a saline placebo, a single intraoral submucosal administration of the benzodiazepine antagonist flumazenil (0.2 mg) is capable of attenuating in 10 minutes or less the central nervous system (CNS) depression produced by a paradigm of stacked sublingual dosing of triazolam (3 doses of 0.25 mg over 90 minutes). |
| NCT00695630 ↗ | Flumazenil Reversal of Oral Triazolam | Completed | University of Washington | Phase 1/Phase 2 | 2006-09-01 | An increase in the utilization of anesthesia and sedation medications by non-anesthesiologists, including dentists, has grown dramatically. This has been prompted, in part, by the need for pharmacological tools to address high levels of fear and anxiety about dental care among the US population and the evidence of oral health disparities among those who are fearful . Given the prevalence of dental fear in the general population and in the various populations with the greatest burden of oral diseases, effective sedation techniques are needed that are safe and effective in the hands of general dentists that make up the "front line" in the efforts to reduce oral health disparities. This study is to determine whether, when compared to a saline placebo, a single intraoral submucosal administration of the benzodiazepine antagonist flumazenil (0.2 mg) is capable of attenuating in 10 minutes or less the central nervous system (CNS) depression produced by a paradigm of stacked sublingual dosing of triazolam (3 doses of 0.25 mg over 90 minutes). |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for triazolam
Condition Name
Clinical Trial Locations for triazolam
Trials by Country
Clinical Trial Progress for triazolam
Clinical Trial Phase
Clinical Trial Sponsors for triazolam
Sponsor Name
